{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:35:41Z","timestamp":1784194541490,"version":"3.55.0"},"reference-count":20,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    There are a few studies on the treatment of sporotrichosis. The standard drug used is itraconazole. However, the use of itraconazole is limited by its interaction with other drugs.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To evaluate the effectiveness and safety of 250 mg terbinafine for the treatment of cutaneous sporotrichosis in patients in whom itraconazole use is not possible.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods\u2002<\/jats:bold>\n                    We performed a descriptive study of cutaneous sporotrichosis cases treated with 250 mg terbinafine for which itraconazole was contraindicated or resulted in severe or moderate pharmacological interactions. Sporotrichosis was diagnosed based on the isolation of\n                    <jats:italic>S. schenckii<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Fifty patients seen between July 2005 and September 2007 were included. Forty\u2010five (92%) patients reported contact with a sick cat and 47 (94%) presented comorbidities (high blood pressure: 64.0%; diabetes mellitus: 30.0%; dyslipidemia: 16.7%; depression: 10.0%; migraine: 2.1%; Parkinson\u00eds disease: 2.1%; peptic ulcer disease: 2.1%; heart failure: 2.1%, and arrhythmia: 2.1%). All patients used some medication interacting with itraconazole (psycholeptics: 36.0%; antidiabetic agents: 28.0%; hypolipemiant agents: 18.0%; calcium\u2010channel blockers: 16.0%; anticonvulsants: 8.0%; cardiotropic drugs: 6.3%; antacids: 6.3%, and antiparkinsonian agent: 2.1%). Most patients (96%) were cured within a mean period of 14 weeks. The drug was discontinued due to a skin rash in one patient. There were no cases of recurrence of the mycosis within a mean follow\u2010up period of 37 weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    This study suggests that 250 mg\/day terbinafine is an effective and well\u2010tolerated alternative to drug therapy of cutaneous sporotrichosis in a population in which itraconazole use is not possible.\n                  <\/jats:p>","DOI":"10.1111\/j.1468-3083.2009.03306.x","type":"journal-article","created":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T06:27:54Z","timestamp":1246429674000},"page":"1273-1276","source":"Crossref","is-referenced-by-count":54,"title":["Terbinafine (250\u00a0mg\/day): an effective and safe treatment of cutaneous sporotrichosis"],"prefix":"10.1111","volume":"23","author":[{"given":"G","family":"Francesconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AC","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Passos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Galhardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,8]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00436061","article-title":"Epidemiology of sporotrichosis in Latin America","volume":"108","author":"Conti Diaz IA","year":"1989","journal-title":"Mycopathologia"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00437450"},{"key":"e_1_2_5_4_2","first-page":"707","volume-title":"Medical Mycology","author":"Kwon\u2010Chung KJ","year":"1992"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/313607"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/522765"},{"key":"e_1_2_5_7_2","unstructured":"Micromedex DrugDex E MARTINDALE Terbinafine \u2013 The Complete Drug Referencehttp:\/\/www.thomsonhc.com\/hcs\/librarian\/ND_PR\/Main\/SBK\/2\/PFPUI\/BpY1SQ1yTn4wf\/ND_PG\/PRIH\/CS\/97A06F\/ND_T\/HCS\/ND_P\/Main\/DUPLICATIONSHIELDSYNC\/5B2E6F\/ND_B\/HCS\/PFActionId\/hcs.common.RetrieveDocumentCommon\/DocId\/2679p\/ContentSetId\/30\/SearchTerm\/terbinafine\/SearchOption\/BeginWithReference(last accessed 12 December 2008)."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0507.2003.00953.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.00013.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb00011.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2001.00657.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2336\/nishinihonhifu.56.584"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/381200"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01813.x"},{"key":"e_1_2_5_15_2","unstructured":"Micromedex DrugDex. E MARTINDALE Itraconazole\u2010The Complete Drug Referencehttp:\/\/www.thomsonhc.com\/hcs\/librarian\/ND_PR\/Main\/SBK\/2\/PFPUI\/BpY1SQ1yTn4wf\/ND_PG\/PRIH\/CS\/97A06F\/ND_T\/HCS\/ND_P\/Main\/DUPLICATIONSHIELDSYNC\/5B2E6F\/ND_B\/HCS\/PFActionId\/hcs.common.RetrieveDocumentCommon\/DocId\/2679p\/ContentSetId\/30\/SearchTerm\/Itraconazole\/SearchOption\/BeginWithReference(last accessed 12 December 2008)."},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701742399"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.9.4319-4320.2004"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:MYCO.0000038440.18814.a9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.2.1.85"},{"key":"e_1_2_5_20_2","first-page":"1651","volume-title":"Fitzpatrick's Dermatology in General Medicine","author":"Bub JL","year":"2003"},{"key":"e_1_2_5_21_2","unstructured":"Sandoz Pharmaceuticals Corporation.US product monograph on terbinafine (Lamisil). East Hanover NJ. Sandoz Pharmaceuticals Corporation April 1996."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2009.03306.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2009.03306.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T18:41:42Z","timestamp":1697049702000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2009.03306.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,8]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1111\/j.1468-3083.2009.03306.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03306.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1165786.628844","asserted-by":"object"}]},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,8]]}}}